What’s inside
View ResearchDelve into the ESCAPE trial, an open-label phase II study investigating personalized immunotherapy for critically ill COVID-19 patients. Patients were treated with anakinra or tocilizumab based on immune function tests. Findings suggest anakinra provided more clinical benefit in reducing organ dysfunction, particularly for patients with macrophage activation syndrome (MAS) or complex immune dysregulation (CID) with increased aminotransferases.
Personalized Immunotherapy in Critically Ill COVID-19 Patients
Open-label trial shows personalized immunotherapy using anakinra and tocilizumab improves outcomes in critically ill COVID-19 patients.
Anakinra vs. Tocilizumab for Severe COVID-19
Study compares the effectiveness of anakinra and tocilizumab in treating severe COVID-19 cases, showing better outcomes with anakinra.
Immune Profiling for COVID-19 Treatment
Utilizing immune function tests to guide personalized immunotherapy for critically ill COVID-19 patients.
Biomarkers in COVID-19 Immunotherapy
Ferritin and HLA-DR levels used to determine the appropriate immunotherapy for severe COVID-19 patients.
Clinical Outcomes with Anakinra in COVID-19
Anakinra treatment linked to improved clinical outcomes and reduced severity in critically ill COVID-19 patients.
Comparative Efficacy of Anakinra and Tocilizumab
Study finds anakinra more effective than tocilizumab in reducing SOFA scores and improving respiratory function in severe COVID-19 cases.
.svg)
.jpg)
.webp)
